Pharma: Focus on Our Expertise to Develop New Drugs

Meiji Holdings Co., Ltd. Financial Results - For the FYE March 2016 -

	TOP

	Financial Results - For the FYE March 2016 -

	1. Overview for FYE March 2016

	2. Initiatives to Address Issues FYE March 2017 Guidance FYE March 2017 will Focus on Gaining Secure Foothold for Continued Growth Growth Strategy Food: Health-oriented Food Market is Expanding - Promote Our Unique Value to Increase Market Share Food: Promote Structural Reforms Pharma: Offset NHI Drug Price Revisions to Achieve Further Growth Pharma: Focus on Our Expertise to Develop New Drugs Growth Strategy Food: Realize Solid Growth in Overseas Markets Pharma: Expand overseas business into core business that rivals domestic operations Growth Strategy Strengthen Corporate Governance and Quality Assurance/Control System

	3. Meiji's Approach to Realizing Sustainable Growth

	100 YEARS YOUNG

	Appendix

Pharma: Focus on Our Expertise to Develop New Drugs

ME1111, discovered in-house
Results of Phase II trial released in December last year
Did not achieve anticipated results
Will develop new formulation and redo trial

Udenafil
Suspended development after a comprehensive review of Phase II trial results

Agricultural chemicals
Some promising compounds for the future profit

R&D expenses
Concentrate research fields to effectively inject development expenses